Biosite On Track To Earn First Rapid Stroke Assay Approval With PMA Filing
This article was originally published in The Gray Sheet
Executive Summary
Biosite expects to present data comparing its Triage Stroke Panel to computed axial tomography (CAT) to FDA's Clinical Chemistry & Toxicology Devices Panel this year
You may also be interested in...
NIH/Biosite Licensing Agreement Proposed For Atherosclerosis Gene Markers
Biosite is contemplating exclusively licensing genetic markers from the National Institutes of Health for the early diagnosis of coronary artery disease
NIH/Biosite Licensing Agreement Proposed For Atherosclerosis Gene Markers
Biosite is contemplating exclusively licensing genetic markers from the National Institutes of Health for the early diagnosis of coronary artery disease
Cardiac Markers Clash For Hospital, Lab Space: Biosite Triages R&D Projects
Biosite's pursuit of additional disease markers for its Triage immunoassay meter will continue unabated this summer, even as the company defends BNP test market share from newcomer Abbott Labs and imminent rival Dade Behring